Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

One shot, two viruses: could a combined vaccine shield seniors from RSV and HMPV?

NCT ID NCT07734649

Vaccine Sponsor: Sanofi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This trial is testing an experimental vaccine designed to protect against two respiratory viruses at once: RSV and HMPV. The study involves about 2,400 adults aged 60 and older, who will receive one of several dose levels of the vaccine, a placebo, or a control vaccine. Researchers are measuring how well the vaccine triggers an immune response and monitoring for side effects over 12 months. The goal is to see if a single shot can safely prevent illness from both viruses in older adults.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an experimental bivalent vaccine targeting RSV and HMPV
What this could lead to
If successful, this could lead to a single vaccine that protects older adults against two common respiratory viruses, including HMPV for which no vaccine currently exists.
What could go wrong
This is an early-phase trial testing multiple dose levels, so the optimal dose and safety profile are not yet known. The vaccine may not produce strong enough immunity or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 2,400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 60 years or older on the day of inclusion * Non-childbearing potential (ie, post-menopausal for at least 1 year or surgically sterile) Exclusion Criteria: * History of laboratory-confirmed RSV and/or laboratory-confirmed HMPV infection affecting the participant and/or the participant's household in the previous 12 months * Previous history of myocarditis, pericarditis, and/or myopericarditis * Screening electrocardiogram (ECG) that is consistent with possible myocarditis, pericarditis, and/or myopericarditis or, in the opinion of the investigator, demonstrates clinically relevant abnormalities that may affect participant safety or study results * Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion * Previous history of Guillain-Barré Syndrome * Any vaccine given 4 weeks before or 4 weeks after study intervention * Previous vaccination against RSV and/or HMPV with an investigational or marketed vaccine * Receipt of any mRNA vaccine/product in the 2 months preceding study intervention administration * Has received a blood transfusion or blood-derived products, including immunoglobulins, in the past 3 months * Any screening laboratory parameter with laboratory abnormality \> Grade 1 or deemed clinically significant by the investigator; if deemed appropriate, investigator may repeat these assessments The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy volunteers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy volunteers Human metapneumovirus immunization Respiratory syncytial virus immunization

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    17 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Accel Research Sites - NeuroStudies- Site Number : 8400063

    RECRUITING

    Decatur, Georgia, 30030, United States

  • Accel Research Sites Network - DeLand Clinical Research Unit- Site Number : 8400064

    RECRUITING

    DeLand, Florida, 32720, United States

  • Alliance Clinical - Las Vegas- Site Number : 8400034

    RECRUITING

    Las Vegas, Nevada, 89109, United States

  • Alliance Clinical - San Diego- Site Number : 8400033

    RECRUITING

    San Diego, California, 92120, United States

  • Charlottesville Medical Research- Site Number : 8400062

    RECRUITING

    Charlottesville, Virginia, 22911, United States

  • Coastal Carolina Research Center - North Charleston- Site Number : 8400061

    RECRUITING

    North Charleston, South Carolina, 29405, United States

  • DM Clinical Research - Chicago- Site Number : 8400050

    RECRUITING

    Melrose Park, Illinois, 60160, United States

  • DM Clinical Research - Detroit- Site Number : 8400049

    RECRUITING

    Southfield, Michigan, 48076, United States

  • DM Clinical Research - Philadelphia- Site Number : 8400046

    RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

  • DM Clinical Research - Sugar Land- Site Number : 8400048

    RECRUITING

    Sugar Land, Texas, 77478, United States

  • DM Clinical Research - Tomball- Site Number : 8400045

    RECRUITING

    Tomball, Texas, 77375, United States

  • Hawthorne Health - Gadsden City Pharmacy- Site Number : 8400025

    RECRUITING

    Gadsden, Alabama, 35901, United States

  • Hawthorne Health - Staten Island- Site Number : 8400026

    RECRUITING

    Staten Island, New York, 10309, United States

  • Long Beach Research Institute- Site Number : 8400005

    RECRUITING

    Long Beach, California, 90805, United States

  • Scottsdale Clinical Trials- Site Number : 8400011

    RECRUITING

    Scottsdale, Arizona, 85260, United States

  • Velocity Clinical Research - Austin- Site Number : 8400013

    RECRUITING

    Austin, Texas, 78759, United States

  • Velocity Clinical Research - Lincoln - Valley Road- Site Number : 8400016

    RECRUITING

    Lincoln, Nebraska, 68510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.